Key facts
- It has raised $7.3M; the latest was Later Stage VC ($1.4M) in Jul 2025.
- Notable investors include Hyundai Investment Partners, G.N. Tech Venture Capital, GeneN Investment Partners, Kolmar Holdings, Stonebridge Ventures (Seoul).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Next&Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Next&Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Next&Bio
Developer of a biotechnology research platform designed to discover customized, anti-cancer drug screening and cell therapy platforms. The company's platform monitors and quantitatively detects physiological phenomena of tissue units in a three-dimensional organoid in real-time to model various intractable diseases and study pathogenesis, providing researchers and consumers with a new concept of medicine based on the original technology to produce organoids.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2018
- Employees
- 25
- Website
- nextandbio.com/
- Ownership
- Privately Held (backing)
Next&Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Next&Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Next&Bio in its N-PORT filings yet. We sweep new filings monthly.